HOOKIPA Pharma HOOK Stock
HOOKIPA Pharma Price Chart
HOOKIPA Pharma HOOK Financial and Trading Overview
| HOOKIPA Pharma stock price | 0.8 USD |
| Previous Close | 1.08 USD |
| Open | 1.08 USD |
| Bid | 0 USD x 2900 |
| Ask | 0 USD x 1800 |
| Day's Range | 1.05 - 1.14 USD |
| 52 Week Range | 0.68 - 2.05 USD |
| Volume | 708.01K USD |
| Avg. Volume | 1.3M USD |
| Market Cap | 83.06M USD |
| Beta (5Y Monthly) | 0.820127 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.47 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.47 USD |
HOOK Valuation Measures
| Enterprise Value | -44741872 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.0918368 |
| PEG Ratio (5 yr expected) | -0.08 |
| Price/Sales (ttm) | 5.197542 |
| Price/Book (mrq) | 0.70117956 |
| Enterprise Value/Revenue | -2.8 |
| Enterprise Value/EBITDA | 0.62 |
Trading Information
HOOKIPA Pharma Stock Price History
| Beta (5Y Monthly) | 0.820127 |
| 52-Week Change | -34.35% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.05 USD |
| 52 Week Low | 0.68 USD |
| 50-Day Moving Average | 1.17 USD |
| 200-Day Moving Average | 1.08 USD |
HOOK Share Statistics
| Avg. Volume (3 month) | 1.3M USD |
| Avg. Daily Volume (10-Days) | 1.82M USD |
| Shares Outstanding | 75.22M |
| Float | 50.21M |
| Short Ratio | 0.04 |
| % Held by Insiders | 7.94% |
| % Held by Institutions | 53.21% |
| Shares Short | 68.55K |
| Short % of Float | 0.13% |
| Short % of Shares Outstanding | 0.13% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -473.49% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -26.35% |
| Return on Equity (ttm) | -57.58% |
Income Statement
| Revenue (ttm) | 15.98M USD |
| Revenue Per Share (ttm) | 0.22 USD |
| Quarterly Revenue Growth (yoy) | 119.79% |
| Gross Profit (ttm) | -52966000 USD |
| EBITDA | -72220000 USD |
| Net Income Avi to Common (ttm) | -66627000 USD |
| Diluted EPS (ttm) | -1.04 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 109.6M USD |
| Total Cash Per Share (mrq) | 2 USD |
| Total Debt (mrq) | 5.76M USD |
| Total Debt/Equity (mrq) | 6.9 USD |
| Current Ratio (mrq) | 3.165 |
| Book Value Per Share (mrq) | 1.526 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -24578000 USD |
| Levered Free Cash Flow (ttm) | -29347376 USD |
Profile of HOOKIPA Pharma
| Country | United States |
| State | NY |
| City | New York |
| Address | 350 Fifth Avenue |
| ZIP | 10118 |
| Phone | 431 890 6360 |
| Website | https://www.hookipapharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 156 |
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Q&A For HOOKIPA Pharma Stock
What is a current HOOK stock price?
HOOKIPA Pharma HOOK stock price today per share is 0.8 USD.
How to purchase HOOKIPA Pharma stock?
You can buy HOOK shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for HOOKIPA Pharma?
The stock symbol or ticker of HOOKIPA Pharma is HOOK.
Which industry does the HOOKIPA Pharma company belong to?
The HOOKIPA Pharma industry is Biotechnology.
How many shares does HOOKIPA Pharma have in circulation?
The max supply of HOOKIPA Pharma shares is 11.92M.
What is HOOKIPA Pharma Price to Earnings Ratio (PE Ratio)?
HOOKIPA Pharma PE Ratio is now.
What was HOOKIPA Pharma earnings per share over the trailing 12 months (TTM)?
HOOKIPA Pharma EPS is -3.47 USD over the trailing 12 months.
Which sector does the HOOKIPA Pharma company belong to?
The HOOKIPA Pharma sector is Healthcare.
HOOKIPA Pharma HOOK included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17366.13 USD — |
-0.1
|
9.44B USD — | 17128.71 USD — | 17467.35 USD — | — - | 9.44B USD — |
| NASDAQ Global Select Market Com NQGS | 8495.19 USD — |
-0.11
|
— — | 8378.66 USD — | 8543.96 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 931.02 USD — |
+0.81
|
— — | 921.75 USD — | 934.48 USD — | — - | — — |
- {{ link.label }} {{link}}